BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
BNB$569.17+0.14%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
Relmada Therapeutics stock surged after reporting positive Phase 2 trial results for NDV-01 and announcing a $160 million PIPE financing.
Nektar stock jumped more than 17% in premarket trading after the company reported positive 52-week data from its REZOLVE-AD atopic dermatitis trial.
RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.
Ironwood Pharmaceuticals shares surged more than 30% in premarket trading after the company issued 2026 revenue guidance above Wall Street estimates.
Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in treating congenital hyperinsulinism.
Cogent Biosciences stock jumped 120% after positive Phase 3 PEAK trial results for its GIST drug bezuclastinib.
Artiva Biotherapeutics skyrocketed today after receiving FDA Fast Track status for its AlloNK therapy in refractory rheumatoid arthritis.
BIAFW stock jumped 52% in premarket after new case studies showed CyPath Lung can detect early-stage lung cancer.
PEPG shares jumped 114% on record-setting DM1 trial results and news of a $100M stock offering.
Shares of aTyr Pharma collapsed following disappointing Phase 3 trial results.
Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.
Lyra Therapeutics stock surged in premarket trading after announcing positive Phase 3 trial results for a key treatment.
Although fraught with risk, these biotech exposures bring enormous upside potential.